Paper · 38384459
Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
Huang Y and 10 others. Front Immunol, 2024. Cited by 18 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma. Papers, record 38384459. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38384459
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cholangiocarcinoma | Major topic |
| Leukopenia | Major topic |
| Bile Duct Neoplasms | Major topic |
| Phenylurea Compounds | Major topic |
| Quinolines | Major topic |
| Humans | |
| Immune Checkpoint Inhibitors | |
| Retrospective Studies | |
| Bile Ducts, Intrahepatic |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26,409,434 | Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. | Cancer Lett | 2016 | https://conductscience.org/library/papers/26409434 | PubMed |
| 2 | 36,990,609 | Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/36990609 | PubMed |
| 3 | 33,125,859 | The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. | Cancer Cell | 2021 | https://conductscience.org/library/papers/33125859 | PubMed |
| 4 | 38,319,896 | Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. | NEJM Evid | 2022 | https://conductscience.org/library/papers/38319896 | PubMed |
| 5 | 21,271,364 | Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis. | Curr Gastroenterol Rep | 2011 | https://conductscience.org/library/papers/21271364 | PubMed |
| 6 | 29,141,660 | xCell: digitally portraying the tissue cellular heterogeneity landscape. | Genome Biol | 2017 | https://conductscience.org/library/papers/29141660 | PubMed |
| 7 | 30,761,139 | Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer. | Front Immunol | 2019 | https://conductscience.org/library/papers/30761139 | PubMed |
| 8 | 19,097,774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 9 | 32,359,091 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. | Int J Cancer | 2020 | https://conductscience.org/library/papers/32359091 | PubMed |
| 10 | 29,182,496 | Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29182496 | PubMed |
1 to 10 of 44
See all 44 referencesCited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,137,650 | Hepatic Artery Infusion Chemotherapy for Cholangiocarcinoma in 2025. | Liver Cancer | 2026 | https://conductscience.org/library/papers/42137650 | PubMed |
| 42,052,809 | Hepatic Arterial Infusion Chemotherapy Plus Systemic Chemotherapy, Lenvatinib and PD-(L)1 Inhibitors Versus Systemic Chemotherapy Plus PD-(L)1 Inhibitors in Advanced Intrahepatic Cholangiocarcinoma. | Technol Cancer Res Treat | 2026 | https://conductscience.org/library/papers/42052809 | PubMed |
| 41,465,387 | Molecular Alterations and Pathways in Intrahepatic Cholangiocarcinoma: Available Evidence and New Perspectives. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465387 | PubMed |
| 41,417,116 | Efficacy and safety of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors versus systemic chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors in advanced unresectable cholangiocarcinoma: a retrospective cohort study. | Cancer Immunol Immunother | 2025 | https://conductscience.org/library/papers/41417116 | PubMed |
| 40,809,010 | Postoperative adjuvant hepatic arterial infusion chemotherapy with gemcitabine-cisplatin sequential capecitabine combined with PDL1 inhibitors in resected high-risk intrahepatic cholangiocarcinom: study protocol for a prospective, multicenter, single-arm, phase 2 trial (HgcCP trial). | Front Oncol | 2025 | https://conductscience.org/library/papers/40809010 | PubMed |
| 40,697,239 | Pathological complete response in advanced intrahepatic cholangiocarcinoma was achieved through tri-modal therapy: A case report and review of literature. | World J Gastrointest Oncol | 2025 | https://conductscience.org/library/papers/40697239 | PubMed |
| 40,514,706 | Hepatic artery infusion chemotherapy plus an immune checkpoint inhibitor and lenvatinib for the treatment of biliary tract carcinoma. | World J Surg Oncol | 2025 | https://conductscience.org/library/papers/40514706 | PubMed |
| 40,374,824 | Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40374824 | PubMed |
| 40,303,874 | Liver Transplantation for Non-hepatocellular Carcinoma: The Role of Immune Checkpoint Inhibitors. | J Clin Exp Hepatol | 2025 | https://conductscience.org/library/papers/40303874 | PubMed |
| 39,624,833 | Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39624833 | PubMed |
1 to 10 of 12
See all 12 cited byGenes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| PDCD1 | 5,133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| GEO | GSE255058 |
Source GEO
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38384459
GET https://conductscience.org/api/papers/v1/38384459/references?page=2